Diabetic dyslipidaemia and residual risk in the era of LDL control - PACE-CME

Diabetic dyslipidaemia and residual risk in the era of LDL control

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
Case-Based Learning and Future Directions
Case-Based Learning and Future Directions
MinuteCE®
Case-Based Learning and Future Directions
1.00 program credit
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Muthiah Vaduganathan, MD, MPH
- Jurgen Floege MD
1.00 program credit